Personalized Medicine: Milestone in the Therapy Control of Humanized Antibodies
Complete the form below to unlock access to ALL audio articles.
CENiMED GmbH, BioTeZ Berlin-Buch GmbH and Invitek Gesellschaft fur Biotechnik & Biodesign mbH (company for biotechnology and bio-design) announce their cooperation in the development, production and marketing of Recovery-ELISAs for the therapy control of a new group of therapeutics, the so called humanized antibodies.
Humanized antibodies offer unforeseen potentialities in cancer therapy, e. g. for the treatment of mamma carcinoma. Previous therapy control methods, however, could not avoid overdoses which had caused adverse reactions with the patients.
Recovery-ELISA (R-ELISA) is a patented ELISA technique for the determination of the exact efficacy concentration of the therapeutic antibodies and the therapy control. The automation of this technique will be established by a renowned platform manufacturer and then will be made available for the patients and the pharmaceutical industry.
“For the first time possibilities for a patient-specific therapy with humanized antibodies will be available” expresses Dr. Bendzko, CEO of Invtek Gesellschaft für Biotechnik & Biodesign mbH.
Dr. Pavel Strohner, CEO of BioTeZ Berlin-Buch GmbH and developer of this novel R-ELISA test, is an expert in the field of ELISA technology. The Berlin location is proud of this epochal development. This is yet another demonstration of the potentials and successes of a cooperation of several biotechnological companies.
“This is yet another important milestone for the implementation of personalized medicine with the patients” complements Dr. Volker Muschalek, CEO of CENiMED GmbH.
